Boston Scientific (NYSE:BSX) has completed the acquisition of Nalu Medical, expanding its presence in chronic pain treatment. The company has announced a pending US$14.5b deal for Penumbra, which ...

The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...

LivaNova is Wednesday's IBD Stock Of The Day. After a trio of pullbacks, the medical devices stock is making a run at a flat ...

Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...

At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...

Resonetics said buying Resolution Medical would expand its capabilities in neuromodulation, structural heart and ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...